

University of Groningen

Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis

Mulder, Tessa; Kluytmans-van den Bergh, Marjolein; Vlamincx, Bart; Roos, Daphne; de Smet, Anne Marie; de Vos Tot Nederveen Cappel, Robert; Verheijen, Paul; Brandt, Alexandra; Smits, Anke; van der Vorm, Eric

Published in:

Antimicrobial Resistance and Infection Control

DOI:

[10.1186/s13756-020-00745-2](https://doi.org/10.1186/s13756-020-00745-2)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Mulder, T., Kluytmans-van den Bergh, M., Vlamincx, B., Roos, D., de Smet, A. M., de Vos Tot Nederveen Cappel, R., Verheijen, P., Brandt, A., Smits, A., van der Vorm, E., Bathoorn, E., van Etten, B., Veenemans, J., Weersink, A., Vos, M., van 't Veer, N., Nikolakopoulos, S., Bonten, M., & Kluytmans, J. (2020). Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: results of a multicenter randomized placebo-controlled clinical trial. *Antimicrobial Resistance and Infection Control*, 9(1), [84]. <https://doi.org/10.1186/s13756-020-00745-2>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy


If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

RESEARCH

Open Access



Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: results of a multicenter randomized placebo-controlled clinical trial

Tessa Mulder¹ , Marjolein Kluytmans-van den Bergh^{1,2,3}, Bart Vlamincx⁴, Daphne Roos⁵, Anne Marie de Smet⁶, Robert de Vos tot Nederveen Cappel⁷, Paul Verheijen⁸, Alexandra Brandt⁹, Anke Smits¹⁰, Eric van der Vorm¹¹, Erik Bathoorn¹², Boudewijn van Etten¹³, Jacobien Veenemans¹⁴, Annemarie Weersink¹⁵, Margreet Vos¹⁶, Nils van 't Veer¹⁷, Stavros Nikolakopoulos¹, Marc Bonten^{1,18} and Jan Kluytmans^{1,3*}

Abstract

Background: Surgical site infections (SSIs) are common complications after colorectal surgery. Oral non-absorbable antibiotic prophylaxis (OAP) can be administered preoperatively to reduce the risk of SSIs. Its efficacy without simultaneous mechanical cleaning is unknown.

Methods: The Precaution trial was a double-blind, placebo-controlled randomized clinical trial conducted in six Dutch hospitals. Adult patients who underwent elective colorectal surgery were randomized to receive either a three-day course of preoperative OAP with tobramycin and colistin or placebo. The primary composite endpoint was the incidence of deep SSI or mortality within 30 days after surgery. Secondary endpoints included both infectious and non-infectious complications at 30 days and six months after surgery.

Results: The study was prematurely ended due to the loss of clinical equipoise. At that time, 39 patients had been randomized to active OAP and 39 to placebo, which reflected 8.1% of the initially pursued sample size. Nine (11.5%) patients developed the primary outcome, of whom four had been randomized to OAP (4/39; 10.3%) and five to placebo (5/39; 12.8%). This corresponds to a risk ratio in the intention-to-treat analysis of 0.80 (95% confidence interval (CI) 0.23–2.78). In the per-protocol analysis, the relative risk was 0.64 (95% CI 0.12–3.46).

(Continued on next page)

* Correspondence: jankluytmans@gmail.com

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

³Department of Infection Control, Amphia Hospital, Breda, The Netherlands

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Conclusions: Observational data emerging during the study provided new evidence for the effectiveness of OAP that changed both the clinical and medical ethical landscape for infection prevention in colorectal surgery. We therefore consider it unethical to continue randomizing patients to placebo. We recommend the implementation of OAP in clinical practice and continuing monitoring of infection rates and antibiotic susceptibilities.

Trial registration: The PreCaution trial is registered in the Netherlands Trial Register under [NL5932](#) (previously: NTR6113) as well as in the EudraCT register under 2015-005736-17.

Keywords: Infection control, Preoperative oral antibiotic prophylaxis, Colorectal surgery, Surgical site infection

Background

Surgical site infections (SSIs) are among the most common healthcare-associated infections and affect approximately 10 in every 100 patients who undergo colorectal surgery [1, 2]. SSIs were associated with a substantial increase in morbidity [3] and mortality [4, 5], prolongation of hospital stays [6, 7] and higher healthcare costs [8–11]. Despite the widespread adoption of infection prevention measures aimed at reducing SSIs, the risk remains high, which underlines the importance of exploring additional precautions [2]. In the past, preoperative oral non-absorbable antibiotics were applied as an infection control strategy for colorectal surgery. Because it was assumed that local antibiotics could only be effective in an “empty” colon, simultaneous cleansing was applied with osmotic fluids [12]. Routine use of this cleansing, also referred to as mechanical bowel preparation (MBP), has recently become controversial due to lack of evidence for advantageous effects. At the same time, there are certain disadvantages, like the risk of dehydration, anastomotic leakage, or patient discomfort [13, 14]. At the same time, the oral antibiotics, which were often considered to be part of the MBP bundle, were abandoned even though their efficacy without simultaneous MBP is unclear. Our study aimed to determine the efficacy of preoperative oral non-absorbable antibiotic prophylaxis (OAP) without the routine administration of MBP on the risk of SSIs after elective colorectal surgery.

Methods

An in-depth description of the rationale and methods was published previously [15]. The trial is registered in the Netherlands Trial Register under NL5932.

Trial design, participants and randomization

The study was designed as a double-blind placebo-controlled randomized trial and was conducted from April 2017 through August 2018 in six Dutch hospitals. (Supplementary Table 1) Patients who were scheduled for colorectal surgery and who had no absolute contraindication for the study medication [15] were eligible to participate. Written informed consent was obtained

from all participants. Eligible patients were randomly assigned in a 1:1 ratio to active OAP or placebo. The randomization was performed by an independent pharmacist, using a permuted block design with varying block sizes and stratified per study center. The study's medication was packed in identical containers that were sequentially numbered with unique numbers. The list that linked these unique numbers to the treatment allocation was securely kept at the coordinating pharmacy (Amphia Hospital, Breda, the Netherlands). Everyone who was involved in the study was blinded to the allocation until the end of the study.

Intervention

OAP was a solution of tobramycin (16 mg/mL) and colistin sulphate (20 mg/mL) that was taken four times daily during the three days before surgery. Each dose was 5 mL. Placebo had an identical color, smell, and taste. The study medication was packed in bottles (100 mL) and distributed with 5 mL syringes. The bottles were returned to the hospital after the intervention period and were weighted to estimate treatment compliance. All patients received perioperative intravenous antibiotic prophylaxis according to the national guidelines [16].

Outcomes and safety reporting

Definitions of all outcomes are summarized in Fig. 1 and were described in more detail in the trial protocol [15]. The primary outcome was deep SSI and/or mortality in the 30 days after surgery. The CDC criteria were used to diagnose SSIs [17]. Rectal carriage of HRE comprised extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E), and (non-intrinsic) carbapenem-resistant, tobramycin-resistant and (non-intrinsic) colistin-resistant Gram-negative Enterobacteriaceae. HRE carriage was assessed by selective screening of rectal swabs that were obtained at inclusion and 30 days after surgery. EUCAST clinical breakpoints were used to interpret MICs [18]. Cultures with a transport time of more than 72 h were excluded from analyses as reliability and quality could not be guaranteed. Quality of life was assessed with the Rand-36 questionnaire [19]. This

Endpoints	Definitions
Primary composite endpoint Deep surgical site infection and/or mortality	SSIs were diagnosed according to the CDC criteria
Secondary endpoints 30 days after surgery <ul style="list-style-type: none"> • Superficial surgical site infection • Deep surgical site infection • All-cause mortality • Anastomotic leakage <ul style="list-style-type: none"> • Relaparotomy • Bacteremia • Infection with <i>Clostridium difficile</i> • Infection with a highly resistant Enterobacteriaceae • Rectal colonization with a highly resistant Enterobacteriaceae • In-hospital use of antibiotics 	<ul style="list-style-type: none"> • Superficial incisional infections • Deep incisional and organ/space infections • Evaluated via assessment of the medical record and a phone call. • Clinical or radiological evidence of leakage requiring surgical or radiological intervention • Abdominal reoperation • Blood culture positive for micro-organisms • Stool sample positive for <i>Clostridium difficile</i> toxins • Positive culture for Enterobacteriaceae that produce ESBL or carbapenemase or that acquired quinolone or aminoglycoside resistance • Rectal swabs positive for ESBL-E or Enterobacteria with non-intrinsic resistance to carbapenems, tobramycin or colistin • Defined as days on therapy
6 months after surgery <ul style="list-style-type: none"> • All-cause mortality • Quality of life • Length of hospital stay • Length of ICU stay 	<ul style="list-style-type: none"> • Evaluated by assessment of medical record and/or phone call • Measured with the RAND-36 questionnaire • In days, including all readmissions • In days, including all readmissions

Fig. 1 Definitions of primary and secondary endpoints. SSIs were diagnosed with the CDC criteria [17]. CDC, Centers for Disease Control and Infection Prevention; ESBL-E, extended spectrum beta-lactamase producing Enterobacteriaceae; ICU, intensive care unit; SSI, surgical site infection

standardized questionnaire contains eleven questions to assess the quality of life on nine different scales. The scale scores range from 0 to 100%. Adverse events (AE) related to the study medication were self-reported in a medication diary. Other protocol related AE, Serious Adverse Events (SAE), Serious Adverse Reactions (SARs), and Suspected Unexpected Serious Adverse Reactions (SUSARs) were reported according to Good Clinical Practice guidelines [20].

Study procedures and data collection

An overview of the study procedures is provided in Supplementary Table 2. Demographic patient data, surgery characteristics, and data on the primary and secondary endpoints were collected from the medical records. Whole-genome sequencing was performed of all resistant isolates to identify the presence of acquired resistance genes.

Statistical analysis

Sample size calculation

We assumed a 14.4% baseline incidence and a 40% relative reduction in the primary endpoint to calculate the sample size. This was based on results from a before-after study that was performed in a Dutch teaching hospital where OAP was introduced as a standard of care


before elective colorectal surgery [21]. With a one-sided alpha of 2.5%, power of 80%, and one interim analysis, the final sample size resulted in 966 patients.

Data analysis

Data were analyzed according to the intention-to-treat principle. We calculated crude risks for every outcome and a corresponding risk ratio (RR) and 95% confidence interval (CI) to compare the risks in the intervention arm with the placebo arm. A per-protocol analysis was performed in the 100% compliant population. Continuous outcomes were analyzed using Student's t-test or Mann Whitney U-test, as appropriate. Quality of life after six months was corrected for the baseline scores by calculating the change (delta) in scores. Negative deltas reflect a worse perception of quality of life compared to baseline, whereas positive values reflect improvement. We evaluated whether our study population was a representative sample of the patient population by comparing average baseline characteristics with surveillance data from a Dutch hospital that did not participate in the study. Statistical analyses were performed using R version 3.3.2.

Results

Patient enrollment is shown in Fig. 2. The number of participants and the inclusion period per hospital are



presented in Supplementary Table 3. The trial ended after 18 months when 78 participants (8.1% of the sample size) had been enrolled. All patients completed the intervention period. During the six-month follow-up period, one person was lost to follow-up and four discontinued active participation but gave consent to continue data collection from their medical records.

The baseline characteristics of the participants are shown in Table 1. Thirty-nine patients were included in each treatment arm. The median age was 68 years, and 68% of patients were male. Colorectal malignancies were the indication for surgery in all except one of the patients (98.7%). Even though it was not part of routine care, MBP was applied in 3.8% of the patients. Based on the leftovers of study medication that were returned, we estimated that 57.7% of the patients took all twelve doses of study treatment.

The effect of OAP on primary and secondary outcomes is presented in Table 2. In total, nine (11.5%) patients developed outcome deep surgical site infection; all survived. Four received OAP (4/39; 10.3%) and five placebo (5/39; 12.8%). This corresponds to a risk ratio in

the intention to treat analysis of 0.80 (95% CI [0.23–2.78]). There was no statistical difference between the treatment arms for any of the outcomes, except for a difference in the quality of life after six months that was improved compared to baseline on most scales in patients who had received OAP, and worsened in patients who had received placebo. In the per-protocol analysis, the risk ratio for the primary outcome was 0.64 (95% CI 0.12–3.46). The predictive power for the planned sample size given the observed results (that is, the probability of having a significant result at the end of the study, was for it to be completed, given the observed results in the 78 patients) was 67%. Due to insufficient power, we were unable to perform any of the preplanned subgroup analyses [15].

We collected 66 valid baseline rectal swabs and 62 valid follow-up rectal swabs (Table 3). There is no difference between the carriage of antibiotic-resistant microorganisms between the two treatment arms at baseline or 30 days after surgery. In colistin-resistant isolates, no acquired colistin resistance genes were found. The carriage of tobramycin resistant species was approximately

Table 1 Baseline characteristics

	OAP (N = 39)	Placebo (N = 39)
Age in years	67 (61–72)	69 (61–73)
Male sex	28/39 (71.8)	25/39 (64.1)
ASA classification ≤2	26/38 (68.4)	30/36 (83.3)
Charlson Comorbidity Index		
1–2	22/39 (56.4)	25/39 (64.1)
3–4	9/39 (23.1)	2/39 (5.2)
≥ 5	8/39 (20.5)	12/39 (30.1)
Immunosuppressive therapy ^a	0/39 (0.0)	2/39 (5.2)
BMI in kg/m ³ , median (IQR)	28 (24–31)	26 (23–29)
Obese (BMI > 30)	9/39 (23.1)	5/38 (13.2)
Abdominal surgery in the previous year	1/39 (2.3)	2/39 (5.2)
Oral mechanical bowel preparation	1/39 (2.3)	2/39 (5.2)
Indication for surgery		
Colorectal malignancy	38/39 (97.4)	39/39 (100)
Inflammatory bowel disease	1/39 (2.3)	0/39 (0.0)
Wound class		
Clean-contaminated (class 2)	37/39 (94.9)	39/39 (100)
Contaminated (class 3)	2/39 (5.1)	0/39 (0.0)
Type of resection		
Right sided hemicolectomy	13/39 (33.3)	9/39 (23.1)
Left sided hemicolectomy	2/39 (5.2)	4/39 (10.3)
Sigmoid resection	10/39 (25.6)	8/39 (20.5)
Low anterior resection or rectum amputation	10/39 (25.6)	15/39 (38.5)
(Sub) total colectomy	2/39 (5.2)	0/39 (0.0)
Other	2/39 (5.2)	3/39 (7.7)
Surgical approach		
Laparotomy	4/39 (10.3)	4/39 (10.3)
Laparoscopy ^b	28/39 (72.0)	26/39 (66.7)
Robotic laparoscopy	7/39 (17.8)	9/39 (23.1)
Duration of surgery in minutes, median (IQR)	148 (117–185)	150 (116–215)
Duration >75th percentile ^c	8/38 (21.1)	13/37 (35.1)
Normothermia after procedure	22/28 (78.6)	25/31 (80.1)
Stoma	6/38 (15.8)	14/39 (35.9)
Perioperative intravenous antibiotic prophylaxis	37/39 (94.9)	37/38 (97.3)
Complete compliance to study medication (all 12 doses)	23/33 (69.7)	22/33 (66.7)

Data are presented as n/N with data (%), unless specified otherwise. ASA, American Society of Anesthesiologists; BMI, body mass index; IQR, interquartile range;

OAP, oral antibiotic prophylaxis

^a Because of chemotherapy

^b Of which 6 (15.4%) were converted to open procedures in OAP arm and 1 (2.3%) in placebo arm

^c 75th percentiles of duration of surgery, based on type of resection and approach [22]

40% both at baseline and 30 days after surgery, which was due to acquired tobramycin resistance genes in 9% of the cultures at baseline and 19.4% 30 days after surgery.

Of the eleven SSI that developed, three were confirmed with a microbiological culture, of which two were performed on abdominal pus collected during reoperation and one directly on the incision. (Supplementary

Table 2 Intention-to-treat analysis of OAP on the risk on primary and secondary outcomes

	OAP n/N (%)	Placebo	RR (95% CI)
Deep SSI and/or mortality	4/39 (10.3)	5/39 (12.8)	0.80 (0.23–2.78)
Deep SSI	4/39 (10.3)	5/39 (12.8)	0.80 (0.23–2.78)
30-day mortality	0/39 (0.0)	0/39 (0.0)	N/A
Superficial SSI	1/39 (2.6)	1/39 (2.6)	1.00 (0.06–15.40)
Anastomotic leakage	1/39 (2.6)	2/39 (5.2)	0.50 (0.05–5.29)
Re-operation	3/39 (7.9)	2/39 (5.3)	1.50 (0.27–8.49)
Bacteremia	0/39 (0.0)	0/39 (0.0)	N/A
Infection with HRE	0/39 (0.0)	0/39 (0.0)	N/A
Infection with <i>Clostridium difficile</i>	0/39 (0.0)	0/39 (0.0)	N/A
6-month mortality	0/39 (0.0)	0/39 (0.0)	N/A
	Median (IQR)		P value
In-hospital use of antibiotics, DOT ^a	0.0 (0.0–0.0)	0.0 (0.0–4.0)	1.000
Length of stay, days ^b	7.0 (5.0–13.0)	6.0 (5.0–12.0)	0.497
Length of ICU stay, days ^b	4.0 ^c	0	N/A
	Median delta (IQR)		P value
Quality of life ^d			
Physical functioning	−5.0 (−15.0–5.0)	−10.0 (−20.0–5.0)	0.124
Social role functioning	0.0 (0.0–12.5)	−12.5 (−25.0–0.0)	0.007
Physical role functioning	0.0 (0.0–25.0)	−12.5 (−93.7–0.0)	0.007
Emotional role functioning	0.0 (0.0–0.0)	0.0 (−25.0–0.0)	0.237
Mental health	4.0 (−1.0–13.0)	0.0 (−7.0–8.0)	0.072
Vitality	5.0 (−5.0–10.0)	−10.0 (−20.0–0.0)	0.002
Pain	0.0 (−10.2–10.7)	−11.2 (−23.0–6.1)	0.002
General health perception	7.5 (0.0–15.0)	−5.0 (−15.0–3.75)	0.014
Change in health	0.0 (0.0–50.0)	0.0 (−25.0–0.0)	0.092

Length of (ICU) stay, quality of life and 6-month mortality were assessed 6 months after surgery, all other outcomes were evaluated 30 days after surgery. DOT, days on therapy; HRE, highly resistant Enterobacteriaceae; ICU, intensive care unit; IQR, interquartile range; N/A, not available; OAP, oral antibiotic prophylaxis; RR, risk ratio; sd, standard deviation; SSI, surgical site infections

^a9 patients in the OAP arm and 10 patients in the placebo arm were treated with antibiotics

^bIncluding all readmissions within 6 months

^cOnly 1 patient was admitted to the ICU

^dDelta was calculated by subtracting baseline scores from scores at 6-month follow-up. Negative delta's reflect worse perception of quality of life on compared to baseline. Number of completed follow-up questionnaires: 27 (69.2%) OAP, 32 (82.1%) placebo

Table 4). None of the pathogens cultured were resistant to tobramycin or colistin.

Adverse events during the intervention period are presented in Table 4. Out of the 65 (83.3%) patients who returned their medication diary, 56 (86.2%) patients took at least one dose of study medication. Of those, 24 (42.9%) did not report any side effects. The most adverse events were gastrointestinal side effects. Patients who received OAP more often reported diarrhea compared to those who received a placebo (51.9% versus 20.7%) as well as nausea (11.1% versus none). During the study, there was one SAE, which was a transient ischemic attack that occurred before the start of the intervention

phase. No other adverse events related to either study medication or other study procedures were reported.

To estimate whether our cohort was a representative sample of the patient population, we compared the baseline characteristics with a comparison cohort of 1597 patients. (Supplementary Table 5) Compared to the comparison cohort, the patients in the trial cohort were more often men, (67.9% versus 55.5%), had more colorectal malignancies (98.7% versus 74.5%), more minimally invasive procedures, but less abdominal surgery in the preceding year (3.8% versus 12.0%). The quality of life indicators, as shown in Table 2, all showed a more positive trend in the OAP

Table 3 Rectal carriage of (non-intrinsic) antibiotic resistant microorganisms

	Patients, n/N (%)		P value
	OAP	Placebo	
Baseline			
Number of valid rectal cultures	35/39 (89.7)	31/39 (79.5)	
Rectal carriage of HRE			
ESBL-E	2/35 (5.7)	1/31 (3.2)	1.000
Carbapenem-resistant Gram-negative bacteria	1/35 (2.9)	2/31 (6.5)	0.597
Carbapenemase-gene present	1/35 (2.9)	2/31 (6.5)	0.597
Tobramycin-resistant Gram-negative bacteria	12/35 (34.3)	14/31 (45.2)	0.452
Acquired aminoglycoside resistance gene present	1/35 (2.8)	5/31 (16.1)	0.088
Colistin-resistant Gram-negative bacteria	7/35 (20.0)	6/31 (19.4)	1.000
Acquired colistin resistance gene present	0/35 (0.0)	0/31 (0/0)	0
30 days after surgery			
Number of valid rectal cultures	34/36 (94.4)	28/35 (80.0)	
Rectal carriage of HRE			
ESBL-E	1/34 (2.9)	1/28 (3.6)	1.000
Carbapenem-resistant Gram-negative bacteria	0/34 (0.0)	1/28 (3.6)	0.452
Carbapenemase gene present	0/34 (0.0)	1/28 (3.6)	0.452
Tobramycin-resistant Gram-negative bacteria	15/34 (44.1)	10/28 (35.7)	0.606
Acquired aminoglycoside resistance gene present	7/34 (2.1)	5/28 (17.9)	0.318
Colistin-resistant Gram-negative bacteria	4/34 (11.9)	4/28 (14.3)	0.320
Acquired colistin resistance gene present	0/34 (0.0)	0/28 (0.0)	1.000

Data are presented as n/N (%). P values are estimated using Fisher's exact test. ESBL-E, Extended-Spectrum Beta Lactamase-producing Enterobacteriaceae; OAP, oral antibiotic prophylaxis

Table 4 Adverse events

	Patients, n/N (%)		P value
	OAP	Placebo	
Adverse events related to study medication			
Self-reported side effects during intervention period ^a			
No side effects	13/27 (48.1)	11/29 (37.9)	0.596
Gastro-intestinal side effects			
Diarrhea	14/27 (51.9)	6/29 (20.7)	0.015
Nausea	3/27 (11.1)	0/29	0.065
Stomach ache	7/27 (25.9)	6/29 (20.7)	0.624
Loss of appetite	1/27 (3.7)	0/29	0.296
Flatulence	1/27 (3.7)	3/29 (10.3)	0.335
Other side effects	5/27 (18.5)	4/29	0.630
Serious adverse reaction (SAR)	0/39 (0.0)	0/39 (0.0)	0
Serious unexpected suspected adverse reaction (SUSAR)	0/39 (0.0)	0/39 (0.0)	0
Adverse events related to other study procedures	0/39 (0.0)	0/39 (0.0)	0
Serious adverse event (SAE)	1/39 (2.6)	0/39 (0.0)	1.000

Data are presented as n/N with data. Denominators for the self-reported side effects are based on the number of medication diaries that were returned: OAP 32/39 (82.1%), placebo 33/39 (84.6%). OAP, oral antibiotic prophylaxis

^aSelf-reported in medication diary during the three days of administration of study medication, including all participants who took at least one dose of study medication

group with a significant difference for social, physical, and emotional role functioning.

Discussion

Due to the premature termination of this multicenter, double-blind, placebo-controlled randomized clinical trial, we were unable to determine the efficacy of OAP in terms of the risk of SSI and other postoperative complications.

The use of oral antibiotic prophylaxis in colorectal surgery is a controversial topic. Several studies demonstrated a reduced risk of SSI when OAP was administered before surgery [23, 24]. However, the question of whether preoperative oral antibiotic prophylaxis is effective without MBP remains unanswered as all RCTs published to date combine OAP with MBP. The best available evidence on OAP efficacy is provided by a recent network meta-analysis that aimed to study the best strategy for bowel preparation. This study also emphasized the knowledge gap on OAP without MBP, as the absence of RCTs that included this strategy as a treatment arm forced the authors to estimate the efficacy of OAP based on indirect comparisons only. Though based on indirect comparisons, a significant reduction in organ/space SSIs was found with OAP only, compared to no preparation (OR 0.13 [95% CrI 0.02–0.55]). This strategy was superior to combining OAP with MBP.

Data on the effectiveness of OAP without simultaneous MBP is also provided by several retrospective observational studies that compared the different bowel preparation strategies. These studies reported conflicting results on effectiveness [25–36]. Potential confounding by indication and limited numbers of patients treated with only OAP hamper concluding on the effectiveness of OAP in the absence of MBP and exemplifies the need for well-controlled and adequately powered studies.

We consider the randomized design as a major strength of our study, which facilitated the unbiased assessment of the efficacy of OAP and its potential drug-related side effects. Although the quality of our design is high, selective participation could not be prevented entirely. Unfortunately, not all potential participants were screened. Patients suffering from multiple or more severe comorbidities were not always considered for participation even though they were eligible. This might have had an impact on the generalizability of the study population. Also, multiple other studies were being conducted within this patient population, which competed with our inclusions. Baseline characteristics of our cohort showed potentially relevant differences with those from a historical cohort of patients undergoing colorectal surgery from a different hospital. There are indications that the patients that we included differed from the source population. For example, the percentage of

patients with colorectal malignancy in our cohort was higher. A recently implemented national screening program for colorectal cancer led to the detection of malignancies in an earlier stage. In general, these patients are in a better clinical condition, and surgery is less radical, which lowers the risk of SSI.

Treatment with OAP was associated with a significant improvement in perception of quality of life at six months after surgery. At the same time, worsening was seen for patients treated with a placebo. In the absence of an effect of OAP on any of the clinical outcomes that could have been a possible explanation for this improvement, we suggest further investigation to study whether and how OAP might impact the quality of life.

Because of the small sample size, we were unable to study the safety of OAP thoroughly. However, several patients who received OAP reported mild gastrointestinal side effects and an unappealing taste. When OAP is considered for implementation in the future, patients should be informed about these potential side effects and the necessity of completing the entire three-day course of OAP despite these side effects. Another important safety concern is the risk of developing antibiotic resistance. We found the prevalence of colistin and tobramycin resistance at baseline to be 16.7 and 39.4%, respectively. The prevalence of carriage of tobramycin and colistin-resistant species did not increase in both treatment arms. We compared our findings with the results obtained with the implementation of selective decontamination of the digestive tract (SDD), a comparable antibiotic prophylaxis containing tobramycin, colistin, and nystatin that is used in several Dutch ICUs. In a post hoc analysis of two multicenter trials, it was shown that during SDD use, the prevalence of colistin resistance ranged from 1.7 to 2.8%, and of tobramycin resistance from 6.2 to 8.0%, respectively [37]. Other studies on SDD found a comparable prevalence [38–40]. The selective culture methods that we used in our study are known to have a higher sensitivity to detect antimicrobial-resistant Gram-negative bacteria [41], and may explain the higher prevalence observed compared to other studies. Due to the small number of patients, we were unable to exclude that OAP may increase the risk of developing antibiotic resistance.

Ethical considerations

At the time this trial was initiated, there was no consensus within the Dutch surgical community on whether OAP should be used before colorectal surgery and, as a result, it was not part of clinical care in the vast majority of hospitals. Because of the uncertainty about the efficacy of the intervention, there was clinical equipoise regarding the use of OAP [42]. The shift started when the findings of a single-center before-after study were

published. This before-after study was performed in the same setting without routine MBP administration [21]. In contrast to previous observational studies, the risk of confounding by indication was minimized because OAP was implemented as the standard of care and prescribed to all patients who underwent elective colorectal surgery. After implementation, a 42% reduction was observed in the risk of SSI and mortality within 30 days after surgery (aRR 0.58 [95% CI 0.40–0.79]). Due to the single-center aspect of the study and the risk of residual confounding, a well-controlled study was deemed necessary to confirm the treatment effect.

We faced multiple problems recruiting participants throughout the entire study period despite our efforts to improve the inclusion rate. The unexpectedly low recruitment rate was communicated with the participating hospitals. Supported by the effectiveness found in the observational study, several investigators considered awaiting the trial results unacceptable and decided to implement OAP to reduce SSI rates. We decided to end the trial prematurely, because the assumption of clinical equipoise regarding the administration of OAP was no longer valid, and the use of a placebo was no longer ethically justifiable.

To conclude, we could not evaluate the efficacy of OAP on SSI risk and other postoperative complications after colorectal surgery due to premature termination of this double-blind, placebo-controlled, randomized clinical trial. Due to the loss of clinical equipoise, we will no longer consider the use of placebo in clinical trials on the efficacy of OAP ethics. Considering the current evidence, we recommend the implementation of OAP in clinical practice and the continued monitoring of infection rates and antimicrobial resistance.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s13756-020-00745-2>.

Additional file 1: Supplementary Table 1. Participating hospitals.

Table 2. Overview of study procedures and follow-up. **Table 3.** Overview of progress per study site. **Table 4.** Microorganisms cultured from three patients with SSI. **Table 5.** Comparison of characteristics with data from an observational cohort of elective colorectal surgery patients.

Abbreviations

ASA: American Society of Anesthesiologists; BMI: Body mass index; CI: Confidence interval; DOT: Days on therapy; DSMB: Data safety and monitoring board; eCRF: Electronic case report form; ESBL: Extended-spectrum beta-lactamase; HRE: Highly-resistant Enterobacteriaceae; IQR: Interquartile range; GCP: Good clinical practice; ICU: Intensive care unit; MBP: Mechanical bowel preparation; OAP: Preoperative oral antibiotic prophylaxis; RCT: Randomized controlled trial; RR: Risk ratio; SAE: Serious adverse event; SAR: Serious adverse reaction; SDD: Selective decontamination of the digestive tract; SSI: Surgical site infection; SUSAR: Suspected unexpected serious adverse reaction

Acknowledgments

The PreCaution trial study group consisted of the following experts and investigators:

Coordinating study team: UMC Utrecht: JAJW Kluytmans (Principal investigator), T Mulder, MFQ Kluytmans-van den Bergh, F Kloosterman, MJM Bonten, S Nikolakopoulos; *Amphia Hospital:* NE van 't Veer. *Project advisors:* *Amphia Hospital:* RMPH Crolla, GP van der Schelling; *Clinical centers and local investigators:* *Admiraal de Ruyter Hospital:* RJ de Vos tot Nederveen Cappel, J Veenemans; *Erasmus Medical Center:* ARM Brandt, M Vos; *Meander Medical Center:* PM Verheijen, AJL Weersink; *Reinier de Graaf Gasthuis:* D Roos, E van der Vorm; *Sint Antonius Hospital:* A Smits, B Vlamincx; *University Medical Center Groningen:* E Bathoorn, B van Etten, AMGA de Smet. *Data safety and monitoring board:* RA Coutinho, EGJM Pierik, H Wertheim, MCJ Bootsma. *Independent expert:* MB Ekkelenkamp.

We thank Stichting Apotheek Haarlemse Ziekenhuizen for the development and preparation of the study medication and Microvida Laboratory for Medical Microbiology (location Amphia Hospital) for the processing and analysis of rectal swabs.

Authors' contributions

TM was a member of the coordinating study team and led the writing of the protocol and manuscript, coordinated the submission of the protocol to the Medical Ethics Committee and coordinated manuscript submission. MK was a member of the coordinating study team and provided input into the design of the study, to the writing of the protocol, coordinated the microbiological analysis and contributed to the writing of the manuscript. BV was a local investigator and provided input into the manuscript. DR was a local investigator and provided input into the protocol and the manuscript. AMdS was a local investigator and provided input into the design of the study, the writing of the protocol and the manuscript. RV was a local investigator and provided input into the manuscript. PV was a local investigator and provided input into the manuscript. AB was a local investigator and provided input into the manuscript. AS was a local investigator and provided input into the manuscript. EvdV was a local investigator and provided input into the manuscript. BvE was a local investigator and provided input into manuscript. JV was a local investigator and provided input into the manuscript. AW was a local investigator and provided input into the manuscript. MV was a local investigator and provided input into the manuscript. NvtV was the coordinating trial pharmacist and provided input into the protocol. SN provided statistical input to the protocol and is the statistician on the trial. MB was a member of the coordinating study team and contributed to the design of the study and provided input into the protocol and the manuscript. JK was a member of the coordinating study team and as principal investigator of the trial, contributed to the design of the study and was a contributor to the protocol and to the writing of the manuscript. All authors read and approved the final manuscript.

Funding

The PreCaution trial was funded by Netherlands Organization for Health Research and Development (ZonMw, project number 522002011).

Availability of data and materials

The metadata file is available on the DataverseNL data repository <https://dataverse.nl/dataset.xhtml?persistentId=doi:10.4111/7BKGVB>.

Ethics approval and consent to participate

The Medical Ethics Committee of the UMC Utrecht (Utrecht, The Netherlands) has reviewed and approved the study (METC number 16/374). This trial was conducted in agreement with the declaration of Helsinki (Version 10, Fortaleza, October 2013), in accordance with the Medical Research Involving Human Subjects Act (WMO) and with the GCP guidelines issued by the European Union. The PreCaution trial is registered in the Netherlands Trial Register under NL5932 (previously: NTR6113) as well as in the EudraCT register under 2015-005736-17.

Consent for publication

All participants gave written informed consent for publication of the obtained data.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. ²Amphia Academy Infectious Disease Foundation, Amphia Hospital, Breda, The Netherlands. ³Department of Infection Control, Amphia Hospital, Breda, The Netherlands. ⁴Department of Medical Microbiology, St. Antonius Hospital, Nieuwegein, the Netherlands. ⁵Department of Surgery, Reinier de Graaf Gasthuis, Delft, The Netherlands. ⁶Department of Intensive Care Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ⁷Department of Surgery, Admiraal de Ruyter Hospital, Goes, The Netherlands. ⁸Department of Surgery, Meander Medical Center, Amersfoort, The Netherlands. ⁹Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands. ¹⁰Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands. ¹¹Department of Medical Microbiology, Reinier de Graaf Gasthuis, Delft, The Netherlands. ¹²Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. ¹³Department of Surgery, University Medical Center Groningen, Groningen, The Netherlands. ¹⁴Department of Medical Microbiology, Admiraal de Ruyter Hospital, Goes, the Netherlands. ¹⁵Department of Medical Microbiology, Meander Medical Center, Amersfoort, The Netherlands. ¹⁶Department of Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands. ¹⁷Department of Clinical Pharmacy, Amphia Hospital, Breda, The Netherlands. ¹⁸Department of Medical Microbiology, Utrecht University Medical Center, Utrecht University, Utrecht, The Netherlands.

Received: 24 March 2020 Accepted: 29 May 2020

Published online: 15 June 2020

References

1. PREZIES. Referentiecijfers POWI 2012–2016.; 2017. <https://www.rivm.nl/documenten/referentiecijfers-powi-2012-2016>. Accessed 15 Jan 2019.
2. ECDC. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2016 – Surgical Site Infections. Stockholm; 2016. <https://ecdc.europa.eu/sites/portal/files/documents/AER-HCAI-SSI.pdf>. Accessed 21 Dec 2018.
3. Cassini A, Plachouras D, Eckmanns T, et al. Burden of six healthcare-associated infections on European population health: estimating incidence-based disability-adjusted life years through a population prevalence-based Modelling study. *PLoS Med*. 2016;13(10):1–16. <https://doi.org/10.1371/journal.pmed.1002150>.
4. Astagneau P, Rioux C, Golliot F, Brückner G. Morbidity and mortality associated with surgical site infections: results from the 1997–1999 INCISO surveillance. *J Hosp Infect*. 2001;48(4):267–74. <https://doi.org/10.1053/jhin.2001.1003>.
5. Bratzler DW. Use of antimicrobial prophylaxis for major surgery. *Arch Surg*. 2005;140(2):174. <https://doi.org/10.1001/archsurg.140.2.174>.
6. Coello R, Charlett A, Wilson J, Ward V, Pearson A, Borriello P. Adverse impact of surgical site infections in English hospitals. *J Hosp Infect*. 2005;60(2):93–103. <https://doi.org/10.1016/j.jhin.2004.10.019>.
7. Shaw E, Gornila A, Piriz M, et al. Multistate modelling to estimate excess length of stay and risk of death associated with organ/space infection after elective colorectal surgery. *J Hosp Infect*. 2018;100(4):400–5. <https://doi.org/10.1016/j.jhin.2018.08.010>.
8. Smith RL, Bohl JK, McElearney ST, et al. Wound infection after elective colorectal resection. *Ann Surg*. 2004;239(5):599–605–607. <https://doi.org/10.1097/01.sla.0000124292.21605.99>.
9. Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection – a European perspective of incidence and economic burden. *Int Wound J*. 2004;1(4):247–73. <https://doi.org/10.1111/j.1742-4801.2004.00067.x>.
10. Graf K, Ott E, Vonberg RP, et al. Surgical site infections-economic consequences for the health care system. *Langenbeck's Arch Surg*. 2011;396(4):453–9. <https://doi.org/10.1007/s00423-011-0772-0>.
11. Badia JM, Casey AL, Petrosillo N, Hudson PM, Mitchell SA, Crosby C. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries. *J Hosp Infect*. 2017;96(1):1–15. <https://doi.org/10.1016/j.jhin.2017.03.004>.
12. Nichols R, Broido P, Condon R, Gorbach S, Nythus L. Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery. *Ann Surg*. 1973;178(4):453–9.
13. Güenaga K, Matos D, Wille-Jørgensen P. Mechanical bowel preparation for elective colorectal surgery (review). *Cochrane Database Syst Rev*. 2011;9:CD001544. <https://doi.org/10.1002/14651858.CD001544.pub4>. www.cochranelibrary.com.
14. Slim K, Martin G. Mechanical bowel preparation before colorectal surgery. Where do we stand? *J Visc Surg*. 2015;153(2):85–7. <https://doi.org/10.1016/j.jvisurg.2015.10.004>.
15. Mulder T, Kluytmans-van den Bergh MFQ, de Smet AMGA, et al. Prevention of severe infectious complications after colorectal surgery using preoperative orally administered antibiotic prophylaxis (PreCaution): study protocol for a randomized controlled trial. *Trials*. 2018;19(1):51. <https://doi.org/10.1186/s13063-018-2439-4>.
16. Bauer MP, van de Garde EMW, van Kasteren MEE, Prins J, Vos M. SWAB Richtlijn Peri-Operatieve Profylaxe. 2017.
17. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. *Infect Control Hosp Epidemiol*. 1992;20(5):271–4. <https://doi.org/10.1086/646436>.
18. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters European Committee on Antimicrobial Susceptibility Testing Breakpoint Tables for Interpretation of MICs and Zone Diameters. 2020. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf. Accessed 13 Jan 2020.
19. ZZee KI van der, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36, een handleiding. Tweede herziene druk. UMCG / Rijksuniversiteit Groningen, Research Institute SHARE. 2012.
20. EMA. Guideline for Good Clinical Practice E6(R2). 2016.
21. Mulder T, Crolla RMPH, Kluytmans-van den Bergh MFQ, et al. Preoperative oral antibiotic prophylaxis reduces surgical site infections after elective colorectal surgery: results from a before-after study. *Clin Infect Dis* 2018;0–2. <https://doi.org/10.1093/cid/ciy839>.
22. PREZIES Referentiecijfers 2014–2018: Postoperatieve Wondinfecties. Tabel 7 50e En 75e Percentiel van de Operatieduur per Ingriep; 2014.
23. Bellows CF, Mills KT, Kelly TN, Gagliardi G. Combination of oral non-absorbable and intravenous antibiotics versus intravenous antibiotics alone in the prevention of surgical site infections after colorectal surgery: a meta-analysis of randomized controlled trials. *Tech Coloproctol*. 2011;15(4):385–95. <https://doi.org/10.1007/s10151-011-0714-4>.
24. Nelson RL, Gladman E, Barbateskovic M. Antimicrobial prophylaxis for colorectal surgery. *Cochrane Database Syst Rev*. 2014;5(5):CD001181. <https://doi.org/10.1002/14651858.CD001181.pub4>.
25. Cannon J, Altom L, Deierhoi R, et al. Oral antibiotics with mechanical bowel preparation reduce infection after elective colorectal resections. *Dis Colon Rectum*. 2012;55(5):e124. <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L71634787>.
26. Kaslow SR, Gani F, Alshaikh HN, Canner JK. Clinical outcomes following mechanical plus oral antibiotic bowel preparation versus oral antibiotics alone in patients undergoing colorectal surgery. *BJS Open*. 2018;2(4):238–45. <https://doi.org/10.1002/bjs.5.66>.
27. Garfinkle R, Abou-Khalil J, Morin N, et al. Is there a role for Oral antibiotic preparation alone before colorectal surgery? ACS-NSQIP analysis by coarsened exact matching. *Dis Colon Rectum*. 2017;60(7):729–37. <https://doi.org/10.1097/DCR.0000000000000851>.
28. Koller SE, Bauer ÁKW, Egleston BL, et al. Comparative Effectiveness and Risks of Bowel Preparation Before Elective Colorectal Surgery. 2018;267(4). <https://doi.org/10.1097/SLA.00000000000002159>.
29. Moghadamyeghaneh Z, Hanna MH, Carmichael JC, et al. Nationwide analysis of outcomes of bowel preparation in colon surgery. *J Am Coll Surg*. 2015;220(5):912–20. <https://doi.org/10.1016/j.jamcollsurg.2015.02.008>.
30. Ohman KA, Wan L, Guthrie T, et al. Combination of Oral antibiotics and mechanical bowel preparation reduces surgical site infection in colorectal surgery. *J Am Coll Surg*. 2017;225(4):465–71. <https://doi.org/10.1016/j.jamcollsurg.2017.06.011>.
31. Toh JWT, Phan K, Ctercteko G, et al. The role of mechanical bowel preparation and oral antibiotics for left-sided laparoscopic and open elective restorative colorectal surgery with and without faecal diversion. *Int J Colorectal Dis*. 2018;33(12):1781–1791. <https://doi.org/10.1007/s00384-018-3166-8>. Epub 2018 Sep 20.

32. Scarborough JE, Mantyh CR, Sun Z, Migaly J. Combined mechanical and Oral antibiotic bowel preparation reduces incisional surgical site infection and anastomotic leak rates after elective colorectal resection. *Ann Surg.* 2015;262(2):331–7. <https://doi.org/10.1097/SLA.0000000000001041>.
33. Atkinson SJ, Swenson BR, Hanseman DJ, et al. In the absence of a mechanical bowel prep, does the addition of pre-operative Oral antibiotics to parental antibiotics decrease the incidence of surgical site infection after elective segmental colectomy? *Surg Infect.* 2015;16(6):728–32. <https://doi.org/10.1089/sur.2014.215>.
34. Shwaartz C, Fields AC, Sobrero M, Divino CM. Does bowel preparation for inflammatory bowel disease surgery matter? *Color Dis.* 2017;19(9):832–9. <https://doi.org/10.1111/codi.13693>.
35. Dolejs SC, Guzman MJ, Fajardo AD, et al. Bowel preparation is associated with reduced morbidity in elderly patients undergoing elective colectomy. *J Gastrointest Surg.* 2017;21(2):372–9. <https://doi.org/10.1007/s11605-016-3314-9>.
36. Midura EF, Jung AD, Hanseman DJ, et al. Combination oral and mechanical bowel preparations decreases complications in both right and left colectomy. *Surgery.* 2018;163(3):528–34. <https://doi.org/10.1016/j.surg.2017.10.023>.
37. Wittekamp BHJ, Oostdijk EAN, Marie A, De Smet GA, Bonten MJM. Colistin and tobramycin resistance during long-term use of selective decontamination strategies in the intensive care unit: a post hoc analysis. *Crit Care.* 2015;19(113):1–6. <https://doi.org/10.1186/s13054-015-0838-4>.
38. Oostdijk EAN, Smits L, de Smet AMGA, Leverstein-van Hall MA, Kesecioglu J, Bonten MJM. Colistin resistance in gram-negative bacteria during prophylactic topical colistin use in intensive care units. *Intensive Care Med.* 2013;39(4):653–60. <https://doi.org/10.1007/s00134-012-2761-3>.
39. Houben AJM, Oostdijk EAN, van der Voort PHJ, et al. Selective decontamination of the oropharynx and the digestive tract, and antimicrobial resistance: a 4 year ecological study in 38 intensive care units in the Netherlands. *J Antimicrob Chemother.* 2014;69(3):797–804. <https://doi.org/10.1093/jac/dkt416>.
40. Daneman N, Sarwar S, Fowler RA, Cuthbertson BH. Effect of selective decontamination on antimicrobial resistance in intensive care units: a systematic review and meta-analysis. *Lancet Infect Dis.* 2013;13(4):328–41. [https://doi.org/10.1016/S1473-3099\(12\)70322-5](https://doi.org/10.1016/S1473-3099(12)70322-5).
41. Kluytmans-van den Bergh MFQ, Verhulst C, Willemsen LE, Verkade E, Bonten MJM, Kluytmans JAJW. Rectal carriage of extended-Spectrum-Beta-lactamase-producing Enterobacteriaceae in hospitalized patients: selective Preenrichment increases yield of screening. *J Clin Microbiol.* 2015;53(8):2709–12. <https://doi.org/10.1128/JCM.01251-15>.
42. Freedman B. Equipoise and the ethics of clinical research. *N Engl J Med.* 1987;317(3):3–16. <https://doi.org/10.1056/NEJM198707163170304>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

